Name | 4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid hydrochloride |
Synonyms | UK-37248 UK-37248-01 Dazoxiben HCl Dazoxiben hydrochloride 4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid hydrochloride |
CAS | 74226-22-5 |
Molecular Formula | C12H13ClN2O3 |
Molar Mass | 268.69622 |
Melting Point | 230-235 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7)) |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
MDL | MFCD00475663 |
In vitro study | Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC 50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production. Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC 50 of 1.60 μM) than in rat whole blood (IC 50 = 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production. |
In vivo study | Dazoxiben (intraperitoneal administration; 100 μg/kg) produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs. |